文献速递前列腺癌

多参数磁共振在前列腺影像报告和数据系统时代对临床显著性前列腺癌的阴性预测价值:系统综述与荟萃分析

Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2020-05-20

该系统综述与荟萃分析纳入42项研究共7321例患者,评估多参数磁共振(mpMRI)对临床显著性前列腺癌(csPCa)的阴性预测值(NPV)。在活检初治男性中,当阴性mpMRI定义为PI-RADS/Likert 1-2且csPCa定义为Gleason分级组≥2时,汇总NPV为90.8%(95%CI 88.1-93.1%);当csPCa定义为Gleason分级组≥3时,NPV为97.1%(95%CI 94.9-98.7%)。结论认为mpMRI总体上是排除csPCa的准确工具,但NPV估计存在异质性,决策应基于本地数据。

要点

  • mpMRI阴性(PI-RADS/Likert 1-2)对Gleason≥2的csPCa汇总NPV为90.8%。
  • mpMRI阴性对Gleason≥3的csPCa汇总NPV可达97.1%。
  • 约7-10%男性若不活检可能漏诊csPCa,决策应结合本地数据。

核心结论

  • 前列腺mpMRI总体上是排除临床显著性前列腺癌的准确检查,但阴性预测值存在异质性,若有本地数据应基于本地数据决策。

研究设计与样本

  • 系统综述与荟萃分析,检索2016年至2019年9月4日的文献,纳入42项研究共7321例患者,以活检或临床随访为参考标准,仅纳入按PI-RADS或类似Likert评分系统解读mpMRI的研究。

主要发现

  • 在活检初治男性中,阴性mpMRI定义为PI-RADS/Likert 1-2且csPCa定义为Gleason分级组≥2时,汇总NPV为90.8%(95%CI 88.1-93.1%)。
  • 当csPCa定义为Gleason分级组≥3时,汇总NPV为97.1%(95%CI 94.9-98.7%)。
  • 阴性mpMRI定义为PI-RADS/Likert 1-3且csPCa定义为Gleason分级组≥2时,汇总NPV为86.8%(95%CI 80.1-92.4%)。
  • 两项研究采用阴性mpMRI和csPCa均定义为较严格标准(PI-RADS/Likert 1-2和Gleason分级组≥3)时,汇总NPV为96.1%(95%CI 93.4-98.2%)。

关键数值与推荐

  • 阴性mpMRI定义1:PI-RADS/Likert 1-2;定义2:PI-RADS/Likert 1-3。
  • csPCa定义1:Gleason分级组≥2;定义2:Gleason分级组≥3。
  • 不同定义组合下NPV分别为90.8%、97.1%、86.8%和96.1%。

临床怎么用

  • 对于年龄特异性前列腺特异抗原升高且mpMRI报告为阴性(或PI-RADS/Likert评分不确定)的男性,NPV可辅助临床医生决定是否不进行活检。
  • 若不进行活检,约7-10%的男性可能漏诊临床显著性前列腺癌,具体取决于设置。
  • 鉴于机构间结果差异,若有本地数据应基于本地数据制定决策。

局限性

  • NPV估计存在异质性。
  • 部分定义组合(如阴性mpMRI和csPCa均采用较严格定义)仅基于两项研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prebiopsy multiparametric magnetic resonance imaging (mpMRI) is increasingly used in prostate cancer diagnosis. The reported negative predictive value (NPV) of mpMRI is used by some clinicians to aid in decision making about whether or not to proceed to biopsy. OBJECTIVE: We aim to perform a contemporary systematic review that reflects the latest literature on optimal mpMRI techniques and scoring systems to update the NPV of mpMRI for clinically significant prostate cancer (csPCa). EVIDENCE ACQUISITION: We conducted a systematic literature search and included studies from 2016 to September 4, 2019, which assessed the NPV of mpMRI for csPCa, using biopsy or clinical follow-up as the reference standard. To ensure that studies included in this analysis reflect contemporary practice, we only included studies in which mpMRI findings were interpreted according to the Prostate Imaging Reporting and Data System (PIRADS) or similar Likert grading system. We define negative mpMRI as either (1) PIRADS/Likert 1-2 or (2) PIRADS/Likert 1-3; csPCa was defined as either (1) Gleason grade group ≥2 or (2) Gleason grade group ≥3. We calculated NPV separately for each combination of negative mpMRI and csPCa. EVIDENCE SYNTHESIS: A total of 42 studies with 7321 patients met our inclusion criteria and were included for analysis. Using definition (1) for negative mpMRI and csPCa, the pooled NPV for biopsy-naïve men was 90.8% (95% confidence interval [CI] 88.1-93.1%). When defining csPCa using definition (2), the NPV for csPCa was 97.1% (95% CI 94.9-98.7%). Calculation of the pooled NPV using definition (2) for negative mpMRI and definition (1) for csPCa yielded the following: 86.8% (95% CI 80.1-92.4%). Using definition (2) for both negative mpMRI and csPCa, the pooled NPV from two studies was 96.1% (95% CI 93.4-98.2%). CONCLUSIONS: Multiparametric MRI of the prostate is generally an accurate test for ruling out csPCa. However, we observed heterogeneity in the NPV estimates, and local institutional data should form the basis of decision making if available. PATIENT SUMMARY: The negative predictive values should assist in decision making for clinicians considering not proceeding to biopsy in men with elevated age-specific prostate-specific antigen and multiparametric magnetic resonance imaging reported as negative (or equivocal) on Prostate Imaging Reporting and Data System/Likert scoring. Some 7-10% of men, depending on the setting, will miss a diagnosis of clinically significant cancer if they do not proceed to biopsy. Given the institutional variation in results, it is of upmost importance to base decision making on local data if available.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sathianathen NJ, Omer A, Harriss E, et al. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. Eur Urol. 2020. PMID: 32444265. doi:10.1016/j.eururo.2020.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。